<DOC>
	<DOC>NCT01018095</DOC>
	<brief_summary>The purpose of this study is to determine if the 2 gram single dose of metronidazole is as effective as the 7 day 500 mg BID dose for treatment of Trichomonas vaginalis (TV) among HIV-infected women.</brief_summary>
	<brief_title>Trichomonas Vaginalis Recurrence Among HIV+ Women</brief_title>
	<detailed_description>This is a Phase IV equivalency trial as both doses of metronidazole are listed in the the Centers for Disease Control and Prevention Treatment Guidelines for the treatment of T vaginalis.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Trichomonas Infections</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>Female 18 years or older HIVpositive TV positive by either wet preparation or culture ability to refrain from all alcohol use for 24 hours before and after taking oral metronidazole willing to take metronidazole treatment pregnant incarcerated previously enrolled currently taking disulfiram alcoholism or known liver damage medical contraindications to metronidazole treated with metronidazole within the previous 14 days requires treatment for B.V. per Amsel's criteria</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>